Qualitative Concept
FDA rejects Defender’s motion sickness treatment
United States Food and Drug Administration, Safety, Effectiveness
Promising Vertex Pain Med Points to New Era for Analgesics
historical period, Analgesics, Opioid, VX-548, Analgesics, Effectiveness, aspects of adverse effects
Gilead Expands Arcus Collaboration with $320M Equity Investment
Investments, Arcus, Gilead, Combined, Phase 3 Clinical Trials
Sanofi gains AATD hopeful with $1.7-billion deal for Inhibrx
sanofi, Inhibrx, Acquisition (action), alpha 1-Antitrypsin Deficiency, Market
Merck details win for Keytruda in bladder cancer after surgery
Keytruda, Malignant neoplasm of urinary bladder, Surgery specialty
Gene editing delivery biotech GenEdit partners with Genentech, raises another $24M
genentech, GenEdit, Gene Modification, Obstetric Delivery
Sarepta shares PhII data for next-gen exon skipping drug, but regulatory pathway is unclear
Regulatory Pathway, Sarepta, next-generation exon-skipping drug, United States Food and Drug Administration, Approved, Muscular Dystrophy, Duchenne, gene therapy, Sarepta’s gene therapy